Heterogeneity of Hormone Receptors and HER2 in Breast Cancer Cutaneous Metastases: An Institutional Experience
International Journal of Molecular Sciences · 04.03.2026 · 27 (5) · 2377
DOI: 10.3390/ijms27052377 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.03.2026. Verfasst von Roberta Iozzo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Pisa University Hospital, Via Roma 57, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Receptors, Progesterone, Receptors, Estrogen, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cutaneous metastases are an uncommon but clinically relevant manifestation of breast cancer (BC), often indicating advanced disease and biological progression. Temporal heterogeneity between primary tumors and metastatic lesions, particularly involving hormone receptors (HRs) and HER2 status, may influence prognosis and treatment decisions. We retrospectively analyzed BC patients with cutaneous metastases diagnosed at a tertiary care center between 2015 and 2024. Clinical data, histopathological features, and immunohistochemical profiles of estrogen receptor (ER), progesterone receptor (PgR), and HER2 were evaluated in paired primary tumors and cutaneous metastatic lesions under uniform pre-analytic and analytic conditions. Receptor discordance and survival outcomes were assessed. Among 660 patients with metastatic BC, 28 (4.2%) developed cutaneous metastases. Median age at diagnosis was 63 years, with chest wall as the most frequent site of skin involvement. HR-positive/HER2-negative tumors were predominant, while triple-negative breast cancer accounted for 19.4% of cases and was associated with a shorter disease course and earlier cutaneous metastatic spread. Receptor discordance occurred in 18.2% for ER, 36.4% for PgR and 41.4% for HER2, mainly involving transitions to or from HER2-low status. After skin involvement, prognosis remained poor. Cutaneous BC metastases show marked receptor heterogeneity, reflecting dynamic tumor evolution. These findings support re-biopsy and biomarker reassessment to guide personalized treatment in metastatic BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Pisa University Hospital, Via Roma 57, 56126 Pisa, Italy.
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
ORCID-Profile: Eugenia Belcastro, Giuseppe Nicolò Fanelli, Paola Ferrari, Andrea Nicolini, Cristian Scatena
Zitieren
APA
Iozzo, R., Belcastro, E., Fanelli, G. N., Cinacchi, P., Ferrari, P., Nicolini, A., & Scatena, C. (2026). Heterogeneity of Hormone Receptors and HER2 in Breast Cancer Cutaneous Metastases: An Institutional Experience. International Journal of Molecular Sciences, 27(5), 2377. https://doi.org/10.3390/ijms27052377
Vancouver
Iozzo R, Belcastro E, Fanelli GN, Cinacchi P, Ferrari P, Nicolini A, et al. Heterogeneity of Hormone Receptors and HER2 in Breast Cancer Cutaneous Metastases: An Institutional Experience. International Journal of Molecular Sciences. 2026;27(5):2377. doi:10.3390/ijms27052377
BibTeX
@article{Iozzo2026,
author = {Iozzo, Roberta and Belcastro, Eugenia and Fanelli, Giuseppe Nicolò and Cinacchi, Paola and Ferrari, Paola and Nicolini, Andrea and Scatena, Cristian},
title = {Heterogeneity of Hormone Receptors and HER2 in Breast Cancer Cutaneous Metastases: An Institutional Experience},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {5},
pages = {2377},
doi = {10.3390/ijms27052377}
}
EUVIMED